Myosin Therapeutics

Executive Summary

Myosin Therapeutics is a Cambridge, MA-based biotech pioneering first-in-class small molecule inhibitors of non-muscle myosin II (NMII), a molecular nanomotor implicated in treatment-refractory diseases. Founded in 2022, the company leverages its proprietary platform to target NMII in oncology and neuroscience, aiming to overcome resistance mechanisms. Its lead program, MYTH-001, is advancing into clinical trials for glioblastoma, a highly aggressive brain cancer with limited treatment options. Preclinical programs in pancreatic cancer, substance use disorder, and musculoskeletal conditions highlight the platform's broad potential. Despite its early stage, Myosin Therapeutics has rapidly progressed from discovery to clinical entry, demonstrating strong platform validation. The company appears to be in Phase 3 (as per its profile), though the lead candidate is only now entering clinical trials—suggesting a possible data discrepancy or rapid advancement. If successful, MYTH-001 could address a significant unmet need in glioblastoma, where standard therapies are often ineffective. Conviction is tempered by the early clinical stage and competitive landscape, but the unique mechanism and focus on resistant diseases offer differentiation.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 trial initiation for MYTH-001 in glioblastoma80% success
• Q1 2027Preclinical proof-of-concept data for pancreatic cancer program50% success
• TBDAnnouncement of strategic partnership or non-dilutive funding40% success